BMS-906024
Systematic (IUPAC) name | |
---|---|
(2R,3S)-N-[(3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)succinamide | |
Identifiers | |
PubChem | CID 66550890 |
ChemSpider | 28536138 |
Chemical data | |
Formula | C26H26F6N4O3 |
Molar mass | 556.500 g/mol |
| |
|
New Phase I drug structure by Bristol-Myers Squibb disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, and colon cancers and leukemia.[1] The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012,[2] and it currently being studied in clinical trials.[3][4]
References
- ↑ C. Drahl, Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA, 2013, http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/
- ↑ http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012129353
- ↑ http://clinicaltrials.gov/show/NCT01653470
- ↑ http://clinicaltrials.gov/show/NCT01292655
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.